万维提示：
1、投稿方式：在线投稿。
2、期刊网址：http://www.intjcancer.org/
https://onlinelibrary.wiley.com/journal/10970215
3、投稿网址：
http://mc.manuscriptcentral.com/ijc-wiley
4、官网邮箱：f.bianchini@dkfz.de（总编）
intjcanc@dkfz-heidelberg.de（编辑部）
intjcanc@dkfz.de（编辑部）
5、官网电话：+49-6221-42-4800（编辑部）
6、期刊刊期：半月刊，每月1日、15日出版。
2021年8月2日星期一
投稿须知【官网信息】
Author Guidelines
1. AIMS & SCOPE
The International Journal of Cancer (IJC) (http://www.intjcancer.org) is the official journal of the Union for International Cancer Control—UICC ; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports in following categories:
Cancer Epidemiology
Cancer Genetics and Epigenetics
Cancer Therapy and Prevention
Infectious Causes of Cancer
Innovative Tools and Methods
Molecular Cancer Biology
Tumor Immunology and Microenvironment
Tumor Markers and Signatures
IJC also publishes Reviews, Letters to the Editor, and, occasionally, Special Reports consisting of invited articles on general topics relevant to cancer research or public health. IJC does not generally publish Case Reports or Meta-analyses. All types of articles undergo full peer review.
IJC is a member of the Committee on Publication Ethics (COPE), and endorses the recommendations issued by COPE and the International Committee of Medical Journal Editors (ICMJE)1.
2. MANUSCRIPT TYPES
2.1 Research Articles and Short Reports
Full research papers should be as concise as possible, without sacrificing documentation of results. Manuscripts containing pertinent and interesting observations concerning cancer research in general, reports on new observations, or studies that do not warrant publication as a full research article will be considered as Short Reports. Research Articles and Short Reports should fit within the categories as outlined below and meet the standards stated therein.
Manuscripts reporting meta-analyses of previously published data might be considered, but are unlikely to be accepted unless they provide new insight into cancer etiology or prevention that was not previously available.
Comprehensive omics studies in humans (e.g., profiling the genome, epigenome, transcriptome, proteome, metabolome, etc.) might be considered as well, but generally require functional verification of emerging candidate tumor-driving factors or, in case of novel markers and signatures, validation of those in independent patient cohorts (see “Tumor markers and signatures”).
Novel experimental assays which hold promise for a more general use in the cancer field are welcome. Manuscripts should provide proof-of-principle experiments using primary tumor material or data.
2.1.1 Cancer Epidemiology
Studies in human populations providing evidence that i) agents/exposures/host-factors pose a carcinogenic risk or are protective; ii) attempt to establish their causal role; iii) identify (sub-) populations at greatest risk; and iv) host–environment interactions are welcome. These include molecular cancer epidemiology approaches in which advanced laboratory methods are integrated. Randomized trials, cohort studies, case–control studies, studies of screening and diagnostic tests, and intervention studies will be considered. Each manuscript should clearly state an objective or hypothesis, the design, and methods (including the source of patients or participants with inclusion/exclusion criteria).
If the authors are describing the results of observational studies, meta-analyses, and randomized trials, the corresponding standard reporting guidelines should be followed (see 5.3.5).
2.1.2 Cancer Genetics and Epigenetics
Genetic and epigenetic studies leading to the identification of factors and biochemical pathways relevant for the pathomechanism of the underlying tumor development are particularly welcome. Epigenetic studies describing either DNA methylation, histone modifications or altered nucleosome structures are encouraged. Studies should be linked to mechanistic studies either explaining epigenetic alterations or outlining the consequences of such events.
2.1.3 Cancer Therapy and Prevention
Reports on new advances in cancer therapy in humans are welcome, especially the results of well-designed randomized trials involving novel (specifically including targeted) therapy strategies or those implicating molecular response indicators to classic or novel (targeted) therapeutics. If the authors are describing the results of a randomized controlled trial, we encourage use of the reporting guidelines in describing the study population (see Ann Intern Med 2010; 152: 726-32, doi:10.7326/0003-4819-152-11-201006010-00232) and we also welcome long-term follow-up studies. If the authors are describing the results of observational studies of therapy, the standards applicable in observational studies in epidemiology should be followed (see 5.3.5). IJC generally does not publish Case Reports.
For mechanistic studies on novel therapeutics we highly encourage having a strong in vivo aspect to support the translational potential of the study.
Novel mechanistic insights derived from experimental models and clinical observations on the cancer-preventive potential of chemical and biological agents, drugs, or food components that revealed a beneficial use in human intervention/cancer prevention studies also fit into this section.
2.1.4 Infectious Causes of Cancer
Contributions to this section should cover novel observations on the role of viral, bacterial, or parasitic infections in human cancers. Mechanistic aspects concerning direct or indirect modes of infectious carcinogens will be of particular interest. Gene expression control and functions of viral oncogenes as well as the discovery of new viruses or other infectious pathogens with growth-stimulating properties for infected cells or tissues will be considered. Indirect modes of carcinogenesis by infections are clearly of interest for the journal. Seroepidemiological and immunological studies related to infectious carcinogens will be considered if they present new data or demonstrate novel links between tumors and infections. The development of vaccines directed against tumor-linked infectious agents and their application is also of substantial interest. We also consider submissions on oncolysis by infectious agents.
2.1.5 Innovative Tools and Methods
Manuscripts describing new bioinformatic or experimental tools or methods that are important for cancer research, diagnostics, treatment and/or prevention are welcome if they hold promise of broad application. Software tools, web-servers and resources must be freely accessible for non-commercial users, and bioinformatic methods should be implemented using publicly available software.
2.1.6 Molecular Cancer Biology
Analytical and functional data on tumor cell characterization (in vitro and in vivo) and on tumor-stroma interactions are very welcome; in particular, novel molecular mechanisms of deregulated cancer cell metabolism and growth regulation, functional role of cancer stem cells for tumor development and progression, as well as novel mechanisms of tumor cell interactions with the microenvironment. Confirmatory findings on additional tumor types, stages, or sites without new functional, diagnostic, or therapeutic implications are not within the scope of the journal.
2.1.7 Tumor Immunology and Microenvironment
This section covers novel findings on the immunological relationship between tumor and host, including all aspects of cellular and humoral immunity directed at tumor and associated stromal cells of the tumor microenvironment. Experimental and clinical studies based on in vivo, ex vivo, and in vitro analysis will be considered. Particularly welcome are studies on new and improved preventive and therapeutic approaches exploiting innate and adaptive immune effects or mechanisms, such as vaccines, check point blockade, or adoptive cell therapy. The potential relevance of newly identified tumor cell-associated T cell epitopes (self- or neoantigen-derived) should be validated by functional in vivo studies.
2.1.8 Tumor Markers and Signatures
This section covers the area of prognostic, predictive, and diagnostic markers from molecular biology studies. We invite papers that explore the development and application of nucleic acid-based, protein-based, serological, and other approaches that identify biomarkers or signatures linked to cancer. Generally, it is required that those markers and signatures are verified in independent patient cohorts and are compared to currently established markers used for the respective clinical application.
2.2 Reviews
Reviews are primarily commissioned by the editors. Presubmission proposals will be considered, and the editors will then indicate whether the review is of potential interest for the journal.
2.3 Letters to the Editor
Comments on published papers, reports on controversial issues, also including negative data that are of general interest or that contradict commonly accepted concepts or hypotheses, will be considered for publication as Letters to the Editor. In the former case, the editors may invite the authors of the paper being questioned to respond, and both Letters may then be published.
2.4 Special Reports
Special Reports will include papers, normally commissioned by Editors, on general topics including guidelines, policies, tumor classification, cancer diagnostics, treatment, prevention and research.
3. MANUSCRIPT PREPARATION
IJC asks authors to ensure that their manuscript meets the journal’s formal requirements as concerns presentation, formatting, and other accompanying documentation upon submission. In the event that papers do not fulfill these formal requirements, the editorial staff will “unsubmit” the manuscript. Authors will be asked to either upload files as needed or correct/revise the paper accordingly. Peer review will not commence until all requirements have been met.
3.1 Manuscript text
All manuscripts should be written in good English and clear phrasing (either British or American spelling). English language editing might be required before the paper is taken into consideration. We strongly suggest that authors who are not native speakers of English have their papers edited before submission. The text file should be in .doc, .docx or .rtf format and start with a title page including short title, full list of authors and affiliations, corresponding author name, affiliation, valid institutional e-mail, and Twitter handles if available, three to five key words, a list of abbreviations used (in alphabetical order), and the appropriate article category. The abbreviations should also be defined the first time they are mentioned in the abstract and text. Research Articles, Special Reports and Short Reports should also include a brief description (max. 75 words) of the “Novelty and Impact” of the work on the title page of the paper. Upon acceptance, this will be edited and presented within the article as “What’s New”. We may publish on our social media platform, and on the “Early View” index, a graphical abstract visually summarizing the main findings of the manuscript. Please feel free to provide a figure to this purpose. The graphical abstract should be different from any other figures already included in the manuscript, and not contain any data items; all content must be in graphical form. Graphical abstracts also have to conform to our standard image rules, as outlined below (see 3.4). All manuscripts except Letters should also contain an unstructured abstract (no sub-headings/sections, maximum 250 words).
3.1.1 Research Articles and Short Reports
Research Articles and Short Reports should follow the IMRAD format (Introduction, Materials and Methods, Results, and Discussion). If appropriate, the results and discussion may be written as one section. Acknowledgments and further disclosures (i.e. conflict of interest, data availability statement and, if applicable ethics statement, disclaimer, funding, etc), References, Figure Legends, and Tables follow the body of the text.
Research Articles should not exceed 5,000 words in length (body of the text from Introduction to Discussion/Conclusions) and may contain a maximum of 50 references and 6 tables/figures in total. For Short Reports, these limitations are 2,500 words, 25 references, and 3 tables/figures in total. Please note that page charges are applied to Research Articles which exceed 8 typeset pages (see 8.1).
3.1.2 Reviews
Reviews should not exceed 4,000 words in length (from Introduction to Discussion/Conclusions) and should be limited to a maximum of 6 tables/figures in total. There is no limit on the number of references.
3.1.3 Letters to the Editor
Letters should report the title of the Letter and begin with “Dear editor”. In case it refers to a published paper, the title should be “Comments on <title of the original paper>” and Replies to Letters should be entitled “Reply to: Comments on <title of the original paper>. A list of abbreviations, statements, the full list of authors and affiliations, and corresponding author contact information should appear at the end of the text. Length should not exceed 1,000 words plus 1 figure or table and 10 references. An abstract is not required.
3.1.4 Special Reports
These papers are generally commissioned by the Editors. The main text should not exceed 2500 words in length and the paper should be limited to 25 references and 3 tables/figures in total. Acknowledgments and further disclosures (i.e. conflict of interest, disclaimer, funding, etc), References, Figure Legends, and Tables follow the body of the text. Additional individual guidance in preparing the reports will be given.
3.2 References
References are listed in a separate reference section immediately following the text. Follow Index Medicus2 for standard journal abbreviations (please see examples below). Number references sequentially in the order cited in the text; do not alphabetize. A reference cited only in a table or figure is numbered in the sequence established by the first mention in the text of the table or figure containing the reference. The corresponding author is responsible for verifying the references that are cited.
Reference to a personal communication or to work in preparation or submitted for publication, is discouraged. However, if such a reference is essential and refers to a written communication, the source is cited parenthetically in the text (not in the reference section) with the comment "unpublished data" or "personal communication”. Written permission from the source that is cited must be sent to the Editorial Office. Reference to a paper accepted but not yet published is listed in the reference section as “in press”. “In press” references must be updated by the authors as soon as publication data are available. Preprints, including the DOI, should be cited in a separate reference list named “Posted on non-commercial preprint servers”.
For review, please provide names of ALL authors in the reference list. At proof stage, however, this will be reduced to 3 names to accommodate our print publication layout. Upon request, the Editorial Office can provide authors with an Endnote style sheet or it can be downloaded via the quick link above.
References to journal articles shall include: ALL authors, article title and subtitle, journal abbreviation, year, volume number in Arabic numerals, and inclusive pages and appear in that order:
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386
Book references are listed as follows: authors, title, edition (if other than the first), volume (if more than one), city, publisher, year, pages:
2. Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM classification of malignant tumors, 7th ed. Chichester: Wiley, 2010. 310p
When referencing a book chapter, the order changes as follows: authors of the chapter, title of the chapter, "In:" editors/authors of the book, title of the book, edition (if there are more than one), volume (if there are more than one), city, publisher, year, and inclusive pages of the chapter:
3. Stilgenbauer S,Lichter P,Döhner H.Genetics of B-Cell Chronic Lymphocytic Leukemia. In: Faguet GB. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Heidelberg: Springer 2004:57–75
3.3 Tables
Tables can be included at the end of the “main document” or submitted as separate files. They are numbered using Arabic numerals. Submit tables in .doc, .docx or .rtf format, exceptionally as .xls or .xlsx for Supplementary Material. All tables should be cited in the text. Each table requires a separate legend.
3.4 Figures
Authors should upload high-quality figures. It is recommended to create the figures in the preferred format required when the paper is accepted:
Line art (graphs, flowcharts, diagrams, scatter plots, and other text-based figures that are not tables) in PDF and 600 – 1000 dpi.
Images (photographs, drawings, imaging system outputs (such as MRIs or ultrasound), and other graphical representations) in TIFF or EPS and 300 dpi.
If a figure includes both, line art and images, the line art requirements apply.
For exceptions during peer review and further details please see: https://authorservices.wiley.com/asset/photos/electronic_artwork_guidelines.pdf).
Figures should be numbered using Arabic numerals. Helvetica or Arial font should be used for any text in the figures, and different panels should be labeled with capital letters in parenthesis (i.e., (A), (B), etc.). All figures, including supplementary figures, should be cited in the text and require a separate legend.
All color figures will be reproduced in full color in the online edition of the journal at no cost to authors. Authors are requested to pay the cost of reproducing color figures in print (see 8.2).
Electrophoretic gel/blots, Photomicrographs and Flow cytometry plots
Any processing and modifications should be disclosed to the editors, who could require the original source data or images at submission or any time during or after the review process. Information present in the original images, however, should not be eliminated, and adjustments of brightness, contrast, or color can be accepted only if applied to the whole image. Grouping of images from different gels or different parts of a gel should be made explicit (e.g. by drawing a line) and stated in the legend. Loading controls must be run on the same gel/blot as the experimental samples. Repeated presentation of data in the manuscript must be clearly declared.
IJC has introduced a procedure of checking manuscripts to ensure the integrity of the data presented in the figures. Authors should be prepared to upload original source data as “Supplementary Material not for review” upon request:
• For all immunoblot images: clearly labeled uncropped, unprocessed original blots including molecular weight markers in one pdf-file. Please make sure that original data of proper loading controls originating from the same gel/blot like the experimental samples are provided as well, even when in the manuscript figure only one representative loading control is shown.
• For photomicrographs: uncropped, unprocessed images including scale bars.
• For flow cytometry plots: raw data underlying flow cytometry plots, as well as a brief description on how data from the raw files were analyzed (e.g. gating strategy) and further processed for creation of the final figure (usage of image editing software for final layout).
3.5 Supplementary Material
Material that is not suitable for print publication such as very long tables, extensive descriptions of already published methods, database information, movies, etc., can be published online as additional supporting information. The final decision to do so, however, lies with the editors. Please submit PDF files for this material; excel tables and movies are also acceptable.
4. MANUSCRIPT SUBMISSION
4.1 Original submissions
Please submit all new manuscripts online at http://mc.manuscriptcentral.com/ijc-wiley. Check by last name to see if you already have an existing account. If you are submitting for the first time, create a new account. Follow the step-by-step instructions for submission. Please note that all correspondence via ScholarOne Manuscripts automatically goes to the submitting author. Therefore, ideally, the corresponding author should submit the paper. Please upload the text in .doc, .docx or .rtf format, the tables in .doc, .docx or .rtf, line-art figures in pdf and 600 – 1000 dpi, and images in .tiff or .eps and and 300 dpi. It is allowed to upload everything in one file for review purposes but, upon acceptance, individual files will be required. Before submission, please check that all uploaded documents, except Supplementary Material, appear correctly in the pdf.
During the online submission process, you will be asked to respond to questions concerning our journal policies. These submission questions and declarations have been designed to reflect best practices in scientific publication.
At the end of a successful submission, a confirmation screen with a manuscript number will appear and the submitting author will receive an e-mail confirming that the manuscript has been received by the journal. If this does not happen, please check your submission and/or contact technical support via the “Help” link.
4.1.1 Cover letter
Please introduce your work in a concise cover letter by addressing the following questions:
What is the aim of the study?
What are the significant and novel findings?
How do these findings relate to the present state of the field?
This text can be used as a basis for the “Novelty and Impact” statements that are required both in the text file and on the online submission page.
The cover letter should also contain any other information about the manuscript or the authors that might be pertinent for the review process, including the DOI of the paper if it has been posted on a non-commercial preprint server.
4.1.2 Authorship agreement and conflict of interest disclosure
Upon submission, the journal requires that the corresponding author ensures and takes responsibility that all coauthors agree to the submission to IJC and agree with the content and presentation of the paper. The corresponding author must also indicate at that time whether any author has a potential conflict of interest as per our policies. Space is provided for this on the ScholarOne Manuscripts submission page. A conflict of interest, even if there is none, should also be stated at the end of the paper. Please note that upon acceptance, we require pen-on-paper signatures from all authors on our Author Agreement Form, including disclosure of the conflict of interest as reported in the paper. We do not accept digital signatures.
4.1.3 Funding
We invite you to enter your sources of funding as part of the submission procedure using FundRef. By using this tool, standardized meta-data can be generated that helps streamline the processing of accepted articles that need to be deposited in funder databases such as PubMed Central. Furthermore, the funding data can be searched in other standardized databases. Funding and grant sponsors should also be mentioned in a statement at the end of the main text or in the Acknowledgements.
4.1.4 Letters of permission
Permission is required from the appropriate investigators when “personal communication” or “unpublished data” is cited in the manuscript, or from another publisher if previously published material has been used in the manuscript.
4.2 Submission of revised manuscripts
4.2.1 Following decisions “minor revisions” and “major revisions”
If you have been invited to submit a revised manuscript, please submit it online via your author center. Instructions can be found there. Enter your point-by-point response to the reviewers’ comments under “View and Respond to Decision Letter”. Upload as main document the copy of the revised paper in which all changes have been highlighted (underlined or marked). Authors should be prepared to upload all uncropped original blots of immunoblot images as “Supplementary Material not for review” upon submission of a revised manuscript.
……
更多详情：
https://onlinelibrary.wiley.com/page/journal/10970215/homepage/forauthors.html
